PETVOTCSurgical & Medical Instruments & ApparatusFiscal year ends March 31
PetVivo Holdings, Inc.
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.75+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- $27.79M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2012 to 2026
Gross margin
66.1%+51.1 pts over 5 years
Operating margin
-793.9%+14780.8 pts over 5 years
Net margin
-917.4%+27090.0 pts over 5 years
Growth rates
Compound annual growth to fiscal 2026
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +0.8% | +7.6% | +146.4% | +31.3% | |
| Gross profit | -24.1% | +2.7% | +231.6% | +26.0% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2017 | FY2021 | FY2026 | Trend |
|---|---|---|---|---|
| Return on equity | -4409.2% | 364.5% | -326.3% | |
| Return on assets | -177.8% | -518.9% | -162.2% | |
| Current ratio | 0.03 | 0.10 | 1.24 | |
| Debt to equity | – | – | 0.00 | |
| Net debt to EBITDA | – | – | 0.02× | |
| Interest coverage | -86.9× | -8.6× | -715.5× | |
| Inventory turnover | – | – | 0.9× | |
| Capex to revenue | 511.9% | 1118.5% | 0.7% | |
| Diluted shares | 2M | 6M | 30M |
Where the cash went
Fiscal 2022 to 2026, five years combined
PetVivo generated $29.82M from operations and spent $958.24K on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$29.82M
Used
$958.24K
Capital expenditure$958.24K100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-917.4%
×Asset turnover0.18×
×Equity multiplier2.01×
=Return on equity, FY2026-326.3%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2026 | -917.4% | 0.18× | 2.01× | -326.3% |
| FY2025 | -741.6% | 0.18× | 2.54× | -342.5% |
| FY2024 | -1130.9% | 0.35× | 3.94× | -1552.9% |
| FY2023 | -950.5% | 0.19× | 1.47× | -259.8% |
| FY2022 | -4338.8% | 0.03× | 1.62× | -197.1% |
| FY2021 | -28007.5% | 0.02× | -0.70× | 364.5% |
| FY2020 | -58047.2% | 0.01× | -0.65× | 221.5% |
| FY2018 | -154790.6% | 0.00× | 3.62× | -488.8% |
| FY2017 | -231916.0% | 0.00× | 24.80× | -4409.2% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2026 against fiscal 2025
3of 9 tests passed in fiscal 2026. Scores of 7 to 9 are usually read as strong.
- ProfitableNet income above zero-$10.47M
- Cash generatingOperating cash flow above zero-$6.11M
- Return on assets improvedROA up on the prior year-269.6% → -112.1%
- Earnings backed by cashOperating cash flow above net income-$6.11M vs -$10.47M
- Less leverageLong-term debt to assets fell0.1% → 0.0%
- Better liquidityCurrent ratio rose1.30 → 1.24
- No dilutionShare count did not rise20M → 30M
- Gross margin improvedGross margin up on the prior year87.84% → 66.11%
- More efficientAsset turnover rose0.36 → 0.12